Tectonic Therapeutic Inc/$TECX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Tectonic Therapeutic Inc

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Ticker

$TECX
Sector
Health
Primary listing
NASDAQ

Employees

51
Headquarters
Watertown, United States
Website
tectonictx.com

TECX Metrics

BasicAdvanced
$321M
-
-$4.03
-
-

Bulls say / Bears say

Cash and cash equivalents totaled $287.4 million as of June 30, 2025, providing a runway into Q4 2028 and sufficient funding to advance key clinical programs without near-term financing needs (Nasdaq )
Complete Part A Phase 1b TX45 data presented at ESC Heart Failure 2025 showed a 19% reduction in PCWP, 18.5% improvement in cardiac output and over 30% reduction in PVR in more severe CpcPH patients, validating TX45’s potential efficacy (Nasdaq )
On June 6, 2025, LifeSci Capital initiated coverage of TECX with an “Outperform” rating and a $84.40 price target, implying roughly 264% upside, underscoring strong institutional conviction in the company’s GEODe platform and pipeline (Nasdaq )
Tectonic reported a net loss of $20.0 million for Q2 2025, up from $12.7 million a year earlier, underscoring continued high cash burn and no path to profitability in the near term (Nasdaq )
TECX’s share price has plunged from a 52-week high of $61.07 to $14.71 as of September 25, 2025, reflecting a nearly 76% decline and highlighting investor skepticism about its clinical and commercial prospects (StockAnalysis )
Key clinical readouts remain distant—TX45 Phase 1b Part B topline data are not expected until early Q4 2025 and Phase 2 results won’t arrive until 2026—exposing the stock to prolonged binary risks without revenue catalysts (Nasdaq )
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TECX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs